Microba Life Sciences News Today

Microba Life Sciences Limited (AU:MAP) has released an update. Microba Life Sciences Limited has announced the cessation of over 22 million options...

Microba Life Sciences Limited (AU:MAP) has released an update. In a recent development, Microba Life Sciences Limited has announced the cessation o...

Microba Life Sciences Limited (AU:MAP) has released an update. Microba Life Sciences Limited has announced the application for quotation of a subst...

Microba Life Sciences Limited (AU:MAP) has released an update. Microba Life Sciences Limited has announced the cessation of its status as a substan...

Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous09.01.2024 / 14:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Mainz Biomed Provides Year-End Corporate Review 2023 European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Co...

Mainz Biomed Provides Year-End Corporate Review 2023...

The company its brokers Bell Potter and Morgans rounding up offers at 23¢ a piece.

With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving diagnostics. For example, Mainz Biomed (NASDAQ: MYNZ) has developled ColoAlert, an affordable test for early detection of Colorectal cancer. As a company specializing in molecular genetic diagnostic solutions for life-threatening conditions, Mainz Biomed also partnered with Microba Life Sciences, a compa

The WHO reports that colorectal cancer is the second most fatal cancer around the world.

Microba Life Sciences ( ASX:MAP ) Full Year 2023 Results Key Financial Results Revenue: AU$5.42m (up 16% from FY 2022...